Role of Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Orlistat based Multidrug Therapy in Glycemic Control, Weight Loss, and Euglycemia in Diabesity: A Real-World Experience

BACKGROUND: This study evaluated the real-world weight loss and glycemic outcomes of multidrug therapy (MDT) according to various combinations of metformin, sodium-glucose cotransporter -2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor analogs (GLP1a), and orlistat in diabesity. METHODS: Data...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Indian J Endocrinol Metab
Autori principali: Dutta, Deep, Jaisani, Ritu, Khandelwal, Deepak, Ghosh, Soumitra, Malhotra, Rajiv, Kalra, Sanjay
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer - Medknow 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6844169/
https://ncbi.nlm.nih.gov/pubmed/31741907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijem.IJEM_185_19
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi